Larimar Therapeutics Statistics
Total Valuation
LRMR has a market cap or net worth of $466.43 million. The enterprise value is $333.65 million.
Important Dates
The last earnings date was Thursday, March 19, 2026, before market open.
| Earnings Date | Mar 19, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
LRMR has 103.88 million shares outstanding. The number of shares has increased by 19.09% in one year.
| Current Share Class | 103.88M |
| Shares Outstanding | 103.88M |
| Shares Change (YoY) | +19.09% |
| Shares Change (QoQ) | +8.76% |
| Owned by Insiders (%) | 1.20% |
| Owned by Institutions (%) | 28.98% |
| Float | 54.99M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.78 |
| P/TBV Ratio | 5.97 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.19, with a Debt / Equity ratio of 0.05.
| Current Ratio | 2.19 |
| Quick Ratio | 2.12 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -132.59% and return on invested capital (ROIC) is -83.23%.
| Return on Equity (ROE) | -132.59% |
| Return on Assets (ROA) | -62.31% |
| Return on Invested Capital (ROIC) | -83.23% |
| Return on Capital Employed (ROCE) | -212.84% |
| Weighted Average Cost of Capital (WACC) | 9.48% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.33M |
| Employee Count | 71 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +74.71% in the last 52 weeks. The beta is 0.97, so LRMR's price volatility has been similar to the market average.
| Beta (5Y) | 0.97 |
| 52-Week Price Change | +74.71% |
| 50-Day Moving Average | 3.96 |
| 200-Day Moving Average | 3.76 |
| Relative Strength Index (RSI) | 49.95 |
| Average Volume (20 Days) | 10,341,088 |
Short Selling Information
The latest short interest is 7.69 million, so 7.41% of the outstanding shares have been sold short.
| Short Interest | 7.69M |
| Short Previous Month | 8.98M |
| Short % of Shares Out | 7.41% |
| Short % of Float | 13.99% |
| Short Ratio (days to cover) | 0.96 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -172.50M |
| Pretax Income | -165.67M |
| Net Income | -165.67M |
| EBITDA | -172.15M |
| EBIT | -172.50M |
| Earnings Per Share (EPS) | -$2.27 |
Full Income Statement Balance Sheet
The company has $136.85 million in cash and $4.07 million in debt, with a net cash position of $132.79 million or $1.28 per share.
| Cash & Cash Equivalents | 136.85M |
| Total Debt | 4.07M |
| Net Cash | 132.79M |
| Net Cash Per Share | $1.28 |
| Equity (Book Value) | 78.09M |
| Book Value Per Share | 0.94 |
| Working Capital | 77.23M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$113.20 million and capital expenditures -$91,000, giving a free cash flow of -$113.29 million.
| Operating Cash Flow | -113.20M |
| Capital Expenditures | -91,000 |
| Depreciation & Amortization | 350,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -113.29M |
| FCF Per Share | -$1.09 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LRMR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -19.09% |
| Shareholder Yield | -19.09% |
| Earnings Yield | -35.52% |
| FCF Yield | -24.29% |
Analyst Forecast
The average price target for LRMR is $16.43, which is 265.92% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $16.43 |
| Price Target Difference | 265.92% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -11.05% |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |